<DOC>
	<DOCNO>NCT01205087</DOCNO>
	<brief_summary>This clinical study design evaluate safety immune modulatory effect oral administration study drug anti-CD3 monoclonal antibody ( MAb ) subject metabolic syndrome .</brief_summary>
	<brief_title>Safety Efficacy Oral Administration Anti-CD3 Monoclonal Antibody ( mAb ) Patients With Metabolic Syndrome</brief_title>
	<detailed_description>PHASE IIa STUDY PROTOCOL A Single-blinded Placebo-controlled Clinical Trial .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<criteria>1 . Subjects complete informed consent process culminate write informed consent subject . 2 . Men woman age 18 75 year ( inclusive ) 3 . Patients biopsy proven NASH within last 3 year 4 . Altered glucose metabolism , include diabetes ( non treat , treat 2 drug ( include insulin ) without change medication least 2 month prior enrollment ) , impaired fast glucose impair glucose tolerance . 5 . HBA1C 5.5 14 % . 1 . Subjects undergone surgery within last 3 month . 2 . Subjects prior gastrointestinal surgery . 3 . Subjects clinically significant infectious , immune mediate malignant disease 4 . Subjects receive elemental diet parenteral nutrition . 5 . Subjects treat type immune modulatory drug include steroid NSAID within last 4 week 6 . Subjects receive either methotrexate cyclosporine anti TNFβ ( infliximab , Remicade ) , antiintegrin ( namixilab ) participate clinical trial within last 3 month . 7 . Subjects history coagulopathy . 8 . Women childbearing potential unless surgically sterile use adequate contraception ( either IUD , oral Depoprovera contraceptive , barrier plus spermicide ) ; pregnant breastfeeding mother . 9 . Subjects , unavailable duration trial , unlikely compliant protocol , felt unsuitable investigator reason . 10 . Subjects HIVpositive . 11 . Subjects HBVpositive 12 . Subjects HCVpositive . 13 . Subjects active CMV 14 . Subjects anemia ( Hb &lt; 10.5 gm/dl ) . 15 . Subjects thrombocytopenia ( platelet &lt; 100K/µl ) . 16 . Subjects lymphopenia ( absolute lymphocyte count &lt; 0.7 ) . 17 . Subjects IgG anticardiolipin antibody &gt; 16 IU . 18 . Prior exposure antiCD3 MAb . 19 . Known sensitivity ingredient study drug 20 . Any know autoimmune disease except studied disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>